Novasep announces strong growth in 2020

Novasep announces strong growth in 2020, in an exceptional context, demonstrating the robustness of its strategic model
- The Group recorded sales of €394M (+46%) and an EBITDA of €63M (+174%)
- Novasep has now completed its Rise-2 strategic plan, a full two years ahead of schedule
- Full deleveraging is in progress following the divestment of the Viral Vector Manufacturing Business in early 2021
Read the press release